It is unclear what will happen to ProKidney's plans for a $458-million, 330-job commercial manufacturing facility in ...

Headquartered in Winston-Salem, ProKidney leases an undetermined amount of space at the general-industrial-zoned building at ...

One of Greensboro’s biggest economic development successes in recent years is now a big bust. ProKidney is a publicly traded ...

ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today ...

“Notably, the FDA also confirmed that ProKidney could consider using eGFR slope as a surrogate endpoint on an accelerated approval pathway for rilparencel. We look forward to continuing our ...

The live webcast for the Evercore fireside chat will be accessible through the“Events” section of the Investor Relations tab within ProKidney's website at . Investors interested in one-on-one ...

ProKidney's stock has seen major swings due to trial results of their lead molecule, rilparencel, but is now back to its previous levels. The company has a complex history with significant ...

WINSTON-SALEM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell ...

ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney's lead product candidate, rilparencel ...

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease ...

The live webcasts will also be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Following the completion of each event ...